Janssen Pharma's Carvykti Gets Positive CHMP Opinion For Earlier Multiple Myeloma Treatment
23/2 13:03
(RTTNews) - The Janssen Pharmaceutical Companies of Johnson & Johnson said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA has recommended the approval of a Type II variation for carvykti (ciltacabtagene autoleucel; cilta-ce...